Podcasts about N1

On this episode of The MacRumors Show, we talk through Apple's all-new M5 chip and the three updated devices it announced containing it this week. Apple this week announced the M5 chip, featuring improved performance and efficiency with a 10-core CPU and 10-core GPU. Apple says the M5 chip offers up to 15% faster CPU performance and up to 45% faster graphics, compared to the M4 chip. It also contains a next-generation GPU architecture optimized for AI tasks, Neural Accelerators for each core, a third-generation ray-tracing engine, enhanced shader cores, and second-generation dynamic caching. There is also a faster 16-core Neural Engine. It has memory bandwidth of 153GB/s and supports up to 32GB of unified memory. The M5 chip comes to the entry-level MacBook Pro, delivering improved performance. It can also now be configured with up to 4TB of storage. The iPad Pro also gains the M5 chip, along with Apple's N1 chip, a new custom-designed wireless networking chip that provides Wi-Fi 7, Bluetooth 6, and Thread. Cellular versions of the new ‌‌iPad Pro‌‌ feature Apple's C1X modem, which allows up to 50% faster cellular data performance than its predecessor, with much greater efficiency. The new ‌‌iPad Pro‌‌ adds the ability to drive external displays at up to 120Hz and now supports Adaptive Sync. The 256GB and 512GB models now start with 12GB of unified memory. The M5 chip is also a key part of a notable update to the Vision Pro. The headset now renders 10% more pixels, can ramp up to a 120Hz refresh rate, and offers three hours of battery life. A new Dual Knit Band feature two straps knitted into a single piece, providing a more comfortable fit. The lower strap has tungsten inserts that provide a counterweight. Apple is also now selling the Logitech Muse spatial stylus for the Vision Pro, and it will begin selling the PlayStation VR2 Sense controller starting next month. Apple's new devices are now available to pre-order, with launch on Wednesday, October 22. This episode is sponsored by Shopify — Sign up for your $1-per-month trial and start selling today at shopify.com/mac.

Clement Manyathela speaks with the listeners on the 42 fatalities in a horrific bus crash on the N1 highway in Limpopo. They touch on the precautions that should be taken by bus companies, they also reflect on what the expectations are with the testimony of Shadrack Sibiya at the ad-hoc commission in parliament. The Clement Manyathela Show is broadcast on 702, a Johannesburg based talk radio station, weekdays from 09:00 to 12:00 (SA Time). Clement Manyathela starts his show each weekday on 702 at 9 am taking your calls and voice notes on his Open Line. In the second hour of his show, he unpacks, explains, and makes sense of the news of the day. Clement has several features in his third hour from 11 am that provide you with information to help and guide you through your daily life. As your morning friend, he tackles the serious as well as the light-hearted, on your behalf. Thank you for listening to a podcast from The Clement Manyathela Show. Listen live on Primedia+ weekdays from 09:00 and 12:00 (SA Time) to The Clement Manyathela Show broadcast on 702 https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/XijPLtJ or find all the catch-up podcasts here https://buff.ly/p0gWuPE Subscribe to the 702 Daily and Weekly Newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook https://www.facebook.com/TalkRadio702 702 on TikTok https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 See omnystudio.com/listener for privacy information.

Send us a textThe Karoo National Park lies a few short kilometres South of Beaufort West. Spectacular scenery, both easy and challenging 4x4 routes, really nice and well situated accommodation, and we got to see the Lions! A night or two here changes Beaufort West from a flying overnight stop on the N1, to a destination.The Road Trip SA app is available for downloadDo you want to visit and explore South Africa? Touch Africa Safaris

Send us a textThe Karoo National Park lies a few short kilometres South of Beaufort West. Spectacular scenery, both easy and challenging 4x4 routes, really nice and well situated accommodation, and we got to see the Lions! A night or two here changes Beaufort West from a flying overnight stop on the N1, to a destination.The Road Trip SA app is available for downloadDo you want to visit and explore South Africa? Touch Africa Safaris

La idea de un Apple TV con chip N1 sería la culminación de 15 años diseñando sus propios chips, la independencia tecnológica que abriría aún más puertas en el ecosistema.Loop Infinito, podcast de Applesfera, de lunes a viernes a las 7.00 h (hora española peninsular). Presentado por Javier Lacort. Editado por Alberto de la Torre.Contacto:

Ακόμη περισσότερες λεπτομέρειες για  τη σειρά iPhone 17 αλλά και τα τσιπ N1 και A19/A19 Pro. Επικοινωνία με την εκπομπή: Email | Facebook Group | Twitter Λεωνίδας Μαστέλλος: Facebook | Twitter | Spotify Μάνος Βέζος: The Vez | Facebook | Twitter | Instagram | Apple Music Apple TV+ Apple TV+ lands “The Off Weeks,” new drama starring and executive produced by Ben Stiller and Jessica Chastain Apple cancels release of new Apple TV+ show previously set to air this Friday Apple Postpones Jessica Chastain Thriller ‘The Savant' Amid Current Events Immersive Video Apple previews new immersive films for Apple Vision Pro Apple Arcade Make history in every era in NBA 2K26 Arcade Edition, launching October 16 on Apple Arcade ‎Play-Doh World FU: watchOS 26 Apple Watch Gets Slow Charger Warnings in watchOS 26 - MacRumors FU: macOS Tahoe macOS Tahoe Features a New Recovery Assistant - MacRumors Your Mac Can Auto-Join an iPhone Hotspot in macOS Tahoe - MacRumors macOS 26 Tahoe Pushes FileVault Use FU: iPhone 17 iPhone 17 Reviews: Choosing the Standard iPhone 'No Longer Means Missing Out' - MacRumors Standard iPhone 17 Outperforms Expectations as Apple Ramps Up Manufacturing - MacRumors FU: iPhone Air iPhone Air Review - MacRumors iPhone Air MagSafe Battery Pack Uses Same Battery as iPhone Air - MacRumors iFixit Teardown Reveals How Apple Made the iPhone Air So Thin - MacRumors iPhone 17 Pro iPhone 17 Pro and iPhone 17 Pro Max Review - MacRumors iPhone 17 Pro teardown: the anodized aluminum scratches badly around the camera plateau edge, the screwed-in battery is a nice repairability upgrade, and more Μπαταρίες iPhone 17 Teardowns Confirm SIM and eSIM-Only Battery Capacities - MacRumors iPhone 17 Pro Max's USB-C Charging Speeds Tested With Apple Chargers - MacRumors Get bent iPhone Air and iPhone 17 Pro Top Last Year's Phones in Bend and Drop Tests Κάμερες iPhone 17 Pro Camera Review: Dolomites — Travel Photographer - Austin Mann Apple N1 Apple debuts N1 networking chip & audio tech to replace Bluetooth Apple's New N1 Chip in iPhone 17, iPhone 17 Pro, and iPhone Air Has a Wi-Fi 7 Limitation - MacRumors One AirPods Pro 3 Feature Upgrade Comes With a Catch - MacRumors Apple A19/A19 Pro Apple Announces A19 and A19 Pro SoCs

durée : 00:02:13 - Basket féminin : le BC Chauray fait ses débuts en N1 ce samedi Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Fyrsti þáttur af Kjaftæðinu. Baldvin Borgarsson, Ásgeir Frank og Alli Davors fara yfir sviðið í fótboltanum. Kjaftæðið er nýtt fótboltahlaðvarp sem er á dagskrá 2x í viku á Fótbolti.net þar sem farið er yfir fótboltasviðið á léttu nótunum. - Hver er maðurinn? - Enski boltinn - Evrópudeildin Íslenski boltinn - Spurningakeppni milli Frank og Alla Samstarfsaðilar Kjaftæðisins eru: Pepsi Max, Ice koffínpúðar, N1-appið, Papco, Súper Burrito, Fiskbúðin Mos og Max Effort. 25% afsláttur fyrir hlustendur Kjaftæðisins fæst á MaxEffort.is með kóðanum "bullshit".

Listen to a recap of the top stories of the day from 9to5Mac. 9to5Mac Daily is available on iTunes and Apple's Podcasts app, Stitcher, TuneIn, Google Play, or through our dedicated RSS feed for Overcast and other podcast players. Sponsored by Backblaze: Never lose a file again. Use code "9to5daily" at checkout for 10% off or try for free. New episodes of 9to5Mac Daily are recorded every weekday. Subscribe to our podcast in Apple Podcast or your favorite podcast player to guarantee new episodes are delivered as soon as they're available. Stories discussed in this episode: iPhone 17 Pro Max easily beats Samsung Galaxy S25 Ultra in battery life test Apple working on MCP support on Mac, iPhone, and iPad Apple explains N1 chip's unique advantages in iPhone 17 Listen & Subscribe: Apple Podcasts Overcast RSS Spotify TuneIn Google Podcasts Subscribe to support Chance directly with 9to5Mac Daily Plus and unlock: Ad-free versions of every episode Bonus content Catch up on 9to5Mac Daily episodes! Don't miss out on our other daily podcasts: Quick Charge 9to5Toys Daily Share your thoughts! Drop us a line at happyhour@9to5mac.com. You can also rate us in Apple Podcasts or recommend us in Overcast to help more people discover the show.

Send us a textBeaufort West lies astride the N1, the main highway that stretches from Cape Town to Beit Bridge. Travellers on the route often use it as a very convenient overnight stop, and there are many really good accommodation options in the area - Lodges on game farms, B&B's, guest houses etc. The Karoo National Park is right there as well - this park and quite a few interesting spots in the town make it a possible destination, rather than a convenient fly-through when on the highway.And a small hint - diesel prices vary greatly in this town - often well over R3.00 per litre difference - use PitStops to find the best prices. www.pitstops.co.za The Road Trip SA app is available for downloadDo you want to visit and explore South Africa? Touch Africa Safaris

Send us a textBeaufort West lies astride the N1, the main highway that stretches from Cape Town to Beit Bridge. Travellers on the route often use it as a very convenient overnight stop, and there are many really good accommodation options in the area - Lodges on game farms, B&B's, guest houses etc. The Karoo National Park is right there as well - this park and quite a few interesting spots in the town make it a possible destination, rather than a convenient fly-through when on the highway.And a small hint - diesel prices vary greatly in this town - often well over R3.00 per litre difference - use PitStops to find the best prices. www.pitstops.co.za The Road Trip SA app is available for downloadDo you want to visit and explore South Africa? Touch Africa Safaris

Themen: Fall Charlie Kirk: Radikale Umdeutungen; NDR stellt neue "KLAR"-Moderatorin vor; Und wofür nutzt Du ChatGPT?; Der letzte Zeitungsjunge von Paris; Serbien: Nachrichtensender N1 in Gefahr; Medienschelte: Da ist er wieder; Moderation: Anja Backhaus Von WDR 5.

Dr. Kathleen Horst, Dr. Rachel Jimenez, and Dr. Yara Abdou discuss the updated guideline from ASTRO, ASCO, and SSO on postmastectomy radiation therapy. They share new and updated recommendations on topics including PMRT after upfront surgery, PMRT after neoadjuvant systemic therapy, dose and fractionation schedules, and delivery techniques. They comment on the importance of a multidisciplinary approach and providing personalized care based on individual patient characteristics. Finally, they review ongoing research that may impact these evidence-based guidelines in the future. Read the full guideline, “Postmastectomy Radiation Therapy: An ASTRO-ASCO-SSO Clinical Practice Guideline” at www.asco.org/breast-cancer-guidelines" TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/breast-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-01747  Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Kathleen Horst, expert panel chair from Stanford University; Dr. Rachel Jimenez, expert panel vice chair from Massachusetts General Hospital; and Dr. Yara Abdou, ASCO representative from the University of North Carolina, authors on "Postmastectomy Radiation Therapy: An American Society for Radiation Oncology, American Society of Clinical Oncology, and Society of Surgical Oncology Clinical Practice Guideline." Thank you for being here today, Dr. Horst, Dr. Jimenez, and Dr. Abdou. Dr. Kathleen Horst: Thank you for having us. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Horst, Dr. Jimenez, and Dr. Abdou who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. Then to dive into the content that we are here today to talk about, Dr. Horst, could you start us off by describing what prompted the update for this joint guideline between ASTRO, ASCO, and SSO, and what is the scope of this 2025 guideline on postmastectomy radiation therapy? Dr. Kathleen Horst: Thank you. This joint guideline was last updated in 2016. Over the past decade, the treatment of breast cancer has evolved substantially. Newer systemic therapy regimens have increasingly personalized treatment based on tumor biology, and local therapy management has explored both the de-escalation of axillary surgery and more abbreviated courses of radiation therapy. Given these advances, it was important to revisit the role of postmastectomy radiotherapy in this modern era of breast cancer therapy. This updated guideline addresses four key questions, including postmastectomy radiation therapy after upfront surgery as well as after neoadjuvant systemic therapy. It also reviews the evolving role of various dose and fractionation schedules and optimal treatment techniques and dose constraints. Brittany Harvey: Excellent. I appreciate that background, Dr. Horst. So then, next, Dr. Jimenez, I would like to review the recommendations of this guideline across those four key questions that Dr. Horst just mentioned. So first, what does the panel recommend for PMRT for patients who received initial treatment with mastectomy? Dr. Rachel Jimenez: The panel provided pretty strong consensus that patients with positive lymph nodes or patients with large tumors involving the skin or the chest wall should receive postmastectomy radiation. However, the panel also recognized that the omission of postmastectomy radiation may be appropriate for select patients who have positive lymph nodes and have an axillary lymph node dissection if they have a low nodal burden and other favorable clinical or pathologic features. For patients without lymph node involvement at the time of surgery and no involvement of the skin or chest wall, postmastectomy radiation was not advised by the panel. Brittany Harvey: Understood. It is helpful to understand those recommendations for that patient population. Following that, Dr. Abdou, what are the key recommendations for PMRT for patients who received neoadjuvant systemic therapy before mastectomy? Dr. Yara Abdou: When we think about PMRT after neoadjuvant treatment, the key point is that the initial stage of presentation still matters a lot. So for example, if a patient comes in with more advanced disease, say a large primary tumor, like a clinical T4, or more extensive nodal disease, like an N2 or N3 disease, those patients should get PMRT, no matter how well they respond to neoadjuvant therapy, because we know it reduces the risk of recurrence and that has been shown pretty consistently. On the other hand, if there are still positive lymph nodes after neoadjuvant treatment, basically residual nodal disease, PMRT is also strongly recommended because the risk of local-regional recurrence is much higher in that setting. The gray area is the group of patients who start with a lower burden of nodal disease, such as N1 disease, but then become node negative at surgery. For those patients, we tend to individualize the decision. So if the patient is young or has triple-negative disease, or if there is a lot of residual disease in the breast even though the nodes are cleared, then radiation is probably helpful. But if everything has melted away with pCR in both the breast and the nodes, then it may be safe to omit PMRT in those patients. For patients with smaller tumors and no nodal involvement to begin with, like a clinical T1-T2 N0, if they are still node negative after neoadjuvant treatment, then PMRT is generally not recommended because their baseline recurrence risk is low. And finally, if the margins are positive and cannot be re-excised, then PMRT is recommended after neoadjuvant therapy. Brittany Harvey: Yes, those distinctions are important for appropriate patient selection. So then, Dr. Horst, we have just reviewed the indications for PMRT, but for those patients who receive PMRT, what are the appropriate treatment volumes and dose fractionation regimens? Dr. Kathleen Horst: The guideline addresses coverage of the chest wall and regional nodes with a specific discussion of the data regarding internal mammary nodal irradiation, which has been an area of controversy over many years. The guideline also reviews the data exploring moderate hypofractionation, or shorter courses of radiation therapy. The task force recommends utilizing moderate hypofractionation for the majority of women requiring postmastectomy radiation, which is likely to have a large impact on clinical practice. This recommendation is based on the evolving data demonstrating that a 3-week course of radiotherapy after mastectomy provides similar oncologic outcomes and minimal toxicity for most patients compared to the standard 5-week treatment course. Brittany Harvey: Thank you for reviewing that set of recommendations as well. So then, Dr. Jimenez, to wrap us up on the key questions here, what delivery techniques are recommended for treating patients who receive PMRT? Dr. Rachel Jimenez: So this portion of the guideline is likely to be most helpful for radiation oncologists because it represents the most technical part of the guideline, but we do believe that it offers some important guidance that has, to this point, been lacking in the postmastectomy radiation setting. So first, the panel recommends that all patients should undergo 3-dimensional radiation planning using CAT scan based imaging, and this includes contouring. So contouring refers to the explicit identification, using a drawing interface on the CAT scan imaging, by the radiation oncologist to identify the areas that are targeted to receive radiation, as well as all of the nearby normal tissues that could receive unintended radiation exposure. And we also provide radiation oncologists in the guideline with suggestions about how much dose each target tissue should receive and what the dose limits should be for normal tissues. Additionally, we make some recommendations regarding the manner in which radiation is delivered. So for example, we advise that when conventional radiation methods are not sufficient for covering the areas of the body that are still at risk for cancer, or where too high of a dose of radiation would be anticipated to a normal part of the body, that providers employ a technique called intensity modulated radiation therapy, or IMRT. And if IMRT is going to be used, we also advise regular 3-dimensional imaging assessments of the patient's body relative to the treatment machine to ensure treatment fidelity. When the treatments are delivered, we further advise using a deep inspiration breath-hold technique, which lowers the exposure to the heart and to the lungs when there is concern for cardiopulmonary radiation exposure, and again, that image guidance be used along with real-time monitoring of the patient's anatomy when those techniques are employed. And then finally, we advise that patients receiving postmastectomy radiation utilize a bolus, or a synthetic substance placed on the patient's skin to enhance radiation dose to the superficial tissue, only when there is involvement of the skin with cancer or other high-risk features of the cancer, but not for every patient who receives postmastectomy radiation. Brittany Harvey: Understood. And then, yes, you just mentioned that section of the guideline is probably most helpful for radiation oncologists, but I think you can all comment on this next question. What should all clinicians, including radiation oncologists, surgical oncologists, medical oncologists, and other oncologic professionals, know as they implement all of these updated recommendations? Dr. Rachel Jimenez: So I think one of the things that is most important when we consider postmastectomy radiation and making recommendations is that this is a multidisciplinary panel and that we would expect and encourage our colleagues, as they interpret the guidelines, to employ a multidisciplinary approach when they are discussing each individual patient with their surgical and medical oncology colleagues, that there is no one size fits all. So these guidelines are intended to provide some general guidance around the most appropriate techniques and approaches and recommendations for the utilization of postmastectomy radiation, but that we recognize that all of these recommendations should be individualized for patients and also represent somewhat of a moving target as additional studies, both in the surgical and radiation oncology realm as well as in the systemic therapy realm, enter our milieu, we have to adjust those recommendations accordingly. Dr. Kathleen Horst: Yeah, I would agree, and I wanted to comment as a radiation oncologist, we recognize that local-regional considerations are intertwined with systemic therapy considerations. So as the data evolve, it is critical to have these ongoing updates in a cross-disciplinary manner to ensure optimal care for our patients. And as Dr. Jimenez mentioned, these multidisciplinary discussions are critical for all of us to continue to learn and understand the evolving recommendations across disciplines but also to individualize them according to individual patients. Dr. Yara Abdou: I could not agree more. I think from a medical oncology perspective, systemic therapy has gotten much better with adjuvant CDK4/6 inhibitors, T-DM1, capecitabine, and immune therapy. So these are all newer adjuvant therapies, so the baseline recurrence risks are lower than what they were in the trials that established PMRT. So the absolute benefit of radiation varies more now, so smaller for favorable biology but still relevant in aggressive subtypes or with residual disease. So it is definitely not a one-size-fits-all. Brittany Harvey: Yes, I think it is important that you have all highlighted that multidisciplinary approach and having individualized, patient-centric care. So then, expanding on that just a little bit, Dr. Abdou, how will these guideline recommendations affect patients with breast cancer? Dr. Yara Abdou: So basically, reiterating what we just talked about, these guidelines really move us towards personalized care. So for patients at higher risk, so those with larger tumors, multiple positive nodes, or residual nodal disease after neoadjuvant therapy, PMRT remains essential, consistently lowering local-regional recurrence and improving survival. But for patients at intermediate or lower risk, the recommendations support a more selective approach. So instead of a blanket rule, we now integrate tumor biology, response to systemic therapy, and individual patient factors to decide when PMRT adds meaningful benefit. So the impact for patients is really important because those at high risk continue to get the survival advantage of radiation while others can be spared the unnecessary treatment and side effects. So in short, we are aligning PMRT with modern systemic therapy and biology, making sure each patient receives the right treatment for their situation. Brittany Harvey: Absolutely. Individualizing treatment to every patient will make sure that everyone can achieve the best outcomes as possible. So then, Dr. Jimenez, to wrap us up, I believe Dr. Horst mentioned earlier that data continues to evolve in this field. So in your opinion, what are the outstanding questions regarding the use of PMRT and what are you looking to for the future of research in this space? Dr. Rachel Jimenez: So there are a number of randomized phase III clinical trials that are either in active accrual or that have reported but not yet published that are exploring further de-escalation of postmastectomy radiation and of axillary surgery. And so we do not yet have sufficient data to understand how those two pieces of information integrate with each other. So for example, if you have a patient who has a positive lymph node at the time of diagnosis and forgoes axillary surgery aside from a sentinel lymph node biopsy, we do not yet know that we can also safely forgo radiation entirely in that setting. So we expect that future studies are going to address these questions and understand when it is appropriate to simultaneously de-escalate surgery and radiation. Additionally, there is a number of trials that are looking at ways in which radiation could be omitted or shortened. So there is the RT CHARM trial, which has reported but not yet published, looking at a shorter course of radiation. And so we do make recommendations around that shorter course of radiation in this guideline, but we anticipate that the additional data from the RT CHARM study will provide further evidence in support of that. Additionally, there is a study called the TAILOR RT trial, which looks at forgoing postmastectomy radiation in patients who, to Dr. Abdou's point, have a favorable tumor biology and a low 21-gene recurrence score. And so we are going to anticipate the results from that study to help guide who can selectively forgo postmastectomy radiation when they fall into that favorable risk category. So there are a number of questions that I think will help flesh out this guideline. And as they publish, we will likely publish a focused update on that information to help provide context for our colleagues in the field and clarify some of these recommendations to suit the latest data. Brittany Harvey: Absolutely. We will look forward to those de-escalation trials and ongoing research in the field to build on the evidence and look for future updates to this guideline. So I want to thank you for your work to update these guidelines, and thank you for your time today, Dr. Horst, Dr. Jimenez, and Dr. Abdou. Dr. Rachel Jimenez: Thank you. Dr. Yara Abdou: Thank you. Dr. Kathleen Horst: Thank you. Brittany Harvey: And then finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/breast-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Welcome and Introduction- Will Townsend welcomes Anshel Sag to episode 236 of G2 on 5G- Overview of the podcast format: six topics covered in about 20 minutesReliance's Upcoming IPO- Reliance preparing for a massive IPO in early 2026- Aiming to raise $6 billion, potentially valuing the company at $112 billion- Discussion on Reliance's network infrastructure and subscriber base- Analysis of the IPO's purpose and potential impact on investorsApple's Latest Product Announcements- Overview of new iPhone 17 series, including the iPhone Air- Introduction of 5G capabilities in all new Apple Watch versions- AirPods Pro 3 features, including improved noise cancellation and heart rate sensor- Discussion on Apple's new chips: A19 SoC, C1X modem, and N1 wireless chipEricsson's AI Framework for Enterprise Networks- Ericsson's Enterprise Wireless Group claims first 5G agentic AI framework- Framework designed to streamline enterprise network operations- Comparison with competitors like HPE and Cisco in the private wireless spaceSpaceX's Spectrum Acquisition from EchoStar- SpaceX's $17 billion transaction for EchoStar's spectrum licenses- Implications for Dish Network and the US mobile carrier landscape- Discussion on potential Starlink direct-to-cell service for Boost Mobile subscribersT-Mobile's Shift Away from CBRS Spectrum- T-Mobile moving past CBRS spectrum for neutral host applications- Analysis of the impact on the CBRS ecosystem and companies like Solana- Discussion on T-Mobile's Advanced Network Solutions (ANS) and private network deploymentT-Mobile's Role in LA 2028 Olympics- T-Mobile for Business to provide 5G connectivity for LA 2028 Olympics- Coverage agreement for over 110 locations across Southern California- Deployment of advanced network solutions, including network slicing and secure connectivityClosing Thoughts- Reflection on the power of 5G for large-scale events like the Olympics- Invitation for listeners to provide insights on specific 5G topics- Request for podcast ratings and subscriptions

Episode 221: Apple's Big September Reveal — AirPods Pro 3, iPhone 17 Lineup, and MoreJay and Karl dig into Apple's September event, covering the latest in AirPods, Apple Watch, iPhone, and the new wireless chips. From heart rate in AirPods to an ultra-slim iPhone Air, here is what matters and why.Full show notes & links:techrant.online/weekly-tech-rant-episode-221/Also available on:Apple Podcasts |YouTubeIn This EpisodeAirPods Apple unveils AirPods Pro 3: new design, better battery life, and a built-in heart rate monitor.Watch Apple Watch Series 11: 5G support and stronger glass. Apple Watch SE 3: S10 chip and always-on display. Apple Watch Ultra 3: larger display, 5G and satellite connectivity, 42-hour battery.iPhone iPhone 17: 120 Hz display on the standard model. iPhone Air: ultra-slim addition to the lineup. iPhone 17 Pro and Pro Max: cosmic orange, unibody design, biggest battery yet, 8× zoom.Other C1X modem: Apple's new in-house modem, successor to C1. N1 chip: Apple's custom silicon for Bluetooth and Wi-Fi radios.Say hello —@WeeklyTechRant |@weeklytechrant.bs

Apple lanzó el iPhone 17 y el iPhone Air: precios, novedades y las burlas que no paranApple celebró su tradicional keynote en Cupertino y presentó el iPhone 17, el iPhone Air ultradelgado, los iPhone 17 Pro y Pro Max, además de los nuevos AirPods Pro 3 y las Apple Watch Series 11, SE3 y Ultra 3. La puesta en escena fue espectacular, como siempre, pero en redes sociales los comentarios no se hicieron esperar: para algunos es una revolución, para otros es “más de lo mismo a precios imposibles”. Nueva gama Apple: iPhone 17 y Air ultrafino con A19, AirPods Pro 3 con traducción, y Apple Watch con 5G, satélite e hipertensión  Por Félix Riaño @LocutorCo iPhone 17: pantalla más grande y memoria mínima de 256 GBEl modelo base de la familia llega con un cambio esperado: la pantalla crece de 6,1 a 6,3 pulgadas, incorpora tecnología ProMotion de 120 Hz y alcanza un brillo máximo de 3.000 nits, algo que mejora mucho la visibilidad en exteriores. Incluye el chip A19 con un motor neuronal de 16 núcleos y soporte para funciones de inteligencia artificial en iOS 26, como traducción en vivo o edición de fotos con IA.La cámara trasera principal es de 48 megapíxeles y se acompaña de un sensor teleobjetivo de 12 MP. La cámara frontal estrena la función “Center Stage”, que te mantiene en el centro del encuadre incluso en videollamadas, y graba en 4K HDR.El precio del iPhone 17 arranca en 799 dólares en Estados Unidos y 969 euros en Europa, con almacenamiento mínimo de 256 GB. Los colores disponibles incluyen lavanda, azul bruma, negro, blanco y verde salvia.iPhone 17 Air: el más delgado de la historia    La gran estrella del evento fue el iPhone 17 Air, con solo 5,6 mm de grosor. Apple lo vende como “el iPhone más delgado y resistente jamás creado”. Tiene un cuerpo de titanio, recubrimiento Ceramic Shield 2 en la parte delantera y trasera, y una pantalla OLED de 6,5 pulgadas.  Lleva el chip A19 Pro, acompañado por los nuevos chips N1 y C1X para Wi-Fi 7, Bluetooth 6 y conectividad más eficiente. El diseño ultrafino obligó a sacrificar algunas cosas: solo incluye una cámara trasera de 48 MP con zoom óptico 2X, la batería es más limitada y desaparece la bandeja para tarjeta SIM física. Todo será mediante eSIM en cualquier país.  El precio del iPhone 17 Air parte de 999 dólares en Estados Unidos y 1.229 euros en Europa.El precio del iPhone 17 Air parte de 999 dólares en Estados Unidos y 1.229 euros en Europa.  iPhone 17 Pro y Pro Max: potencia y cámaras con IA     Los modelos Pro traen lo mejor del hardware de Apple. El chip A19 Pro estrena un nuevo sistema de refrigeración con cámara de vapor para evitar sobrecalentamientos, y la memoria RAM sube a 12 GB. Además, incluyen el módulo de cámaras más grande en un iPhone, con tres sensores de 48 MP cada uno.  El teleobjetivo ahora ofrece zoom de “calidad óptica” hasta 8X, aunque en realidad el zoom óptico puro baja de 5X a 4X, detalle que ya generó críticas en foros especializados. La grabación de video añade soporte para ProRes RAW, Dolby Vision HDR y hasta 4K a 120 fps.  El iPhone 17 Pro arranca en 1.099 dólares y el Pro Max en 1.199 dólares en Estados Unidos, con almacenamiento mínimo de 256 GB y la posibilidad de llegar hasta 2 TB.  AirPods Pro 3: traducción en vivo y sensor cardíaco  Los AirPods Pro 3 mantienen el mismo diseño externo, pero ahora integran un sistema acústico mejorado, cancelación activa de ruido el doble de potente que en la generación anterior, y la gran novedad: traducción en vivo.  Si dos personas tienen AirPods Pro 3, pueden mantener una conversación en diferentes idiomas con traducción casi instantánea. Además, incorporan un sensor de ritmo cardíaco que envía datos directamente a la app Salud y a Fitness+. La autonomía alcanza 8 horas con cancelación activa de ruido.  El precio de lanzamiento es de 249 dólares y estarán disponibles desde el 19 de septiembre.  Apple Watch Series 11, SE3 y Ultra 3: salud y satélites     La Series 11 llega más delgada, con pantalla más resistente y batería de 24 horas. Su gran novedad es la detección de hipertensión, que analiza los vasos sanguíneos durante 30 días para detectar riesgo de presión alta. Además, ahora da un puntaje de sueño para ayudarte a mejorar tu descanso.  La Apple Watch SE3, más económica, añade pantalla siempre encendida, chip S10 y carga rápida. La Ultra 3 está dirigida a deportistas y aventureros, con pantalla más grande, batería de 42 horas y conexión satelital para emergencias.  Los precios: SE3 desde 249 dólares, Series 11 desde 399 y Ultra 3 desde 799.  Críticas y burlas a Apple  Aunque los fanáticos celebran el diseño ultrafino del iPhone Air y las mejoras de cámara en los Pro, los haters no perdonan:Algunos dicen que “Apple inventó la batería corta duración premium”.Otros bromean con que “el zoom óptico adelgazó junto al iPhone Air”.Y muchos critican que funciones como los 120 Hz o la eSIM global ya llevan años en Android.Aun así, se espera que los nuevos modelos rompan récords de ventas gracias al marketing y al ecosistema cerrado que mantiene a millones de usuarios fieles.Disponibilidad  Los nuevos iPhone, AirPods y Apple Watch estarán en preventa desde el 12 de septiembre y saldrán oficialmente a la venta el 19 de septiembre de 2025 en Estados Unidos y Europa. En Latinoamérica, los lanzamientos se irán confirmando país por país en las próximas semanas.   Apple no necesita reinventar la rueda: con un poco de diseño, un chip más rápido y una keynote con frases grandilocuentes, logra que medio mundo hable de sus productos. ¿Tú qué opinas? ¿Vale la pena gastar más de 1.000 dólares en un iPhone 17 Pro, o es mejor seguir con tu viejo celular que todavía aguanta todo el día?Fuentes:Le FigaroLe ParisienAl JazeeraBloombergZDNetNew York Times WirecutterConviértete en un seguidor de este podcast: https://www.spreaker.com/podcast/flash-diario-de-el-siglo-21-es-hoy--5835407/support.

Carlos Alcaraz a remporté son 2e US Open, son 6e titre en Grand Chelem. Une victoire contre Jannik Sinner qui lui permet également de devenir N1 mondial. À l'image de tout son tournoi, l'Espagnol n'a laissé aucune chance à son adversaire sur cette finale. Avec 6 Majeurs à 22 ans, Alcaraz est-il déjà légendaire ? Peut-il aller chercher les records de Nadal, Djokovic et Federer ? Quels sont les prochains objectifs de l'Espagnol ? Dans la 2e partie du Mag, on distribue les tops et les flops de la quinzaine new-yorkaise. 

U najnovijoj epizodi Njuz Podkasta EP203 zaranjamo u epicentar haosa: otkriven je tajni plan Aleksandra Vučića za gašenje N1 i Nove S! Detaljno analiziramo ekskluzivni snimak koji je objavio KRIK i pitamo se da li je ovo kraj slobodnih medija u Srbiji. Pored toga, vraćamo se na uzavreli avgust i proteste "Srbija protiv nasilja". Komentarišemo najbizarnije trenutke – od Vučićeve povrede na staklu i tuče naprednjaka u Veterniku, do viralnih scena sa momkom sa fajtalicom. Zaranjamo u fenomen "Ćacilenda", analiziramo hapšenje Tome Mone i Vesićevu bolest, i ne zaobilazimo sramotu sa pismom Gardijanu. Na kraju, bavimo se opasnim napadom vlasti na Univerzitet i Filozofski fakultet i Đukinom idejom o pobedi "stranačke pešadije".

On today's Eastern Lariat, it's an extremely special episode as Dylan is joined by the esteemed Pro Wrestling Author Dr. Jonathan Foye. The Ganbaru Author and regular Japanese wrestling live show attendee joins Fox in giving looks at all the competitors in the tournament, their histories, who they are as wrestlers and also we come through at the end with predictions for the finals of the tournament as well as the winner. It was great to have the good doctor on once again and to talk about the company he loves, with insight and info abound!   For more coverage of Japanese wrestling, and wrestling past and present please check out our Patreon for literally 1000s of hours of audio and written content as well: https://www.patreon.com/easternlariat    Follow us on Twitter/X:     https://www.twitter.com/easternlariat    https://www.twitter.com/strigga       https://www.twitter.com/viva_zero   www.twitter.com/JonathanFoye   Follow us on BlueSky: @easternlariat.bsky.social @vivazero.bsky.social @strigga.bksy.social   Follow us on IG: https://www.instagram.com/easternlariat   Check out Jonathan's books on AJPW/NOAH at the turn of the century!   https://www.amazon.com/Ganbaru-Japan-Wrestling-Survived-Roster/dp/B09RWJ56KR   https://www.amazon.com/Muto-Years-Jonathan-Foye/dp/B0BHKGL3Y3/

Vai su https://saily.com/astroviktor o usa il coupon astroviktor su app e sito per avere il 15% di sconto sul tuo primo acquisto su Saily!Scarica la GUIDA GRATUITA https://astroviktor.it/guide-astroviktor/come-lavorare-nello-spazio/

Send us a textChuck shares his eye-opening experience at BICSI Beyond 2025 in Las Vegas, revealing industry shifts and technological developments that will impact ICT professionals. The conference highlighted alarming workforce demographics and showcased emerging technologies that could transform how cable installation is performed.• Introduction to Challenge Coins as special recognition tokens for major contributors to the podcast• Recording of interviews with John Daniels (BICSI CEO), Chuck Wilson, and Matt Affel from the JATC• Participation in multiple committee meetings including the new ICT Lifecycle Management Training Committee• Updates on industry standards including revisions to the N1, N2, and N3 documents• Insights from Matthew Griffin's keynote about AI's impact on ICT, including cable-pulling robots• Industry statistics showing 67% of low voltage workers are over 40 and only 13% under 30• Revelation of 9.9 million job vacancies in the low voltage industry• Exhibit hall highlights including new cable testing technology from Trend NetworksIf you enjoy this content, please consider becoming a Patreon member to support the podcast. Your contributions help me represent your interests at industry events and committees while creating valuable content for the ICT community.Support the showKnowledge is power! Make sure to stop by the webpage to buy me a cup of coffee or support the show at https://linktr.ee/letstalkcabling . Also if you would like to be a guest on the show or have a topic for discussion send me an email at chuck@letstalkcabling.com Chuck Bowser RCDD TECH#CBRCDD #RCDD

主持人Anita和美國任恩儀教授的對話探討了資優生的定義、特徵及其評估方法，深入分析了智商與成就之間的關係，並討論了家長在孩子教育過程中的焦慮與期待。 本次對話探討了教育中天賦與環境的關係，強調了情緒發展與挫折應對的重要性。家長在教育中的角色和策略也被深入分析，特別是在自由教育和創造力培養方面。對資優生的社會偏見與挑戰，以及未來教育的方向與人文關懷也成為討論的重點。認識任恩儀教授個人網站  Whole Child Lens Lab https://www.wholechildlens.com/網站好讀中文版 全面發展實驗室 https://www.wholechildlens.com/zh-twIG https://www.instagram.com/wholechildlens/臉書專頁輕鬆聊  N1的田野筆記  https://www.facebook.com/n1.fieldnotes[本集重點摘要]・資優生的定義不僅僅是智商的高低，而是一個綜合的檔案概念。・資優生的評估需要考慮多種因素，包括語言、數學等領域的能力。・智商與成就之間存在一定的正相關，但並不是唯一的決定因素。・諾貝爾獎得主並不一定是智商最高的人，成功的因素多樣。・家長的焦慮往往源於對孩子未來的期望與不確定性。・資優生的特質可能在三四歲時就會顯露出來。・教育資源的提供對資優生的發展至關重要。・資優生的評估應根據年齡段進行，確保公平性。・不同國家在資優生評估標準上可能存在差異。・資優生的教育應注重個性化與多樣化的培養。 教育不僅僅是知識的傳授，更是情感的培養。・孩子的聰明才智需要在適當的環境中發展。・家長的引導對孩子的成長至關重要。・資優教育應關注孩子的情緒與創造力。・資優生可能面臨情感與社交的挑戰。・教育公平是實現每個孩子潛能的關鍵。・挫折教育是孩子成長的重要一環。・家長應理解孩子的情感需求，給予支持。・創造力的培養需要在日常生活中滲透。‧未來教育應更加注重人文關懷與情感教育。 「徐豫切入點」節目合作來信：case@riverwalk.cc 私訊分享請IG https://www.instagram.com/anita.neuro/

Et si l'on pouvait un jour voir sans yeux ? C'est le pari audacieux que s'est lancé Neuralink, la société d'Elon Musk. Après avoir implanté avec succès son premier dispositif cérébral N1 sur des patients paralysés, l'entreprise s'attaque désormais à un défi encore plus vertigineux : redonner une forme de vision à des personnes aveugles, même privées de nerf optique.Ce nouveau projet porte un nom évocateur : Blindsight. Il ne s'agit pas ici de restaurer une vision naturelle, mais de créer une perception visuelle fonctionnelle, grâce à une interface cerveau-machine. En clair, une caméra capte l'environnement, le système transforme l'image en signaux électriques, et stimule directement le cortex visuel du patient. Résultat espéré : permettre aux aveugles de reconnaître des visages, lire, se déplacer, accomplir des tâches du quotidien.Pour y parvenir, Neuralink s'est entourée de chercheurs de l'Université de Californie à Santa Barbara et de l'université Miguel Hernández, en Espagne. L'étude est encore en phase exploratoire. Les premiers tests se font sur des patients déjà équipés d'un implant existant, le CORTIVIS, afin d'expérimenter différents modes de stimulation. Des volontaires voyants participent aussi, pour comparer les ressentis.L'intelligence artificielle joue un rôle central dans cette aventure : elle doit analyser les scènes visuelles et faire ressortir les éléments essentiels, afin que la stimulation soit la plus pertinente possible. L'objectif n'est pas d'imiter la vue, mais de construire une représentation utile du monde. Pour l'instant, Blindsight n'a pas encore été testé sur des humains avec les implants Neuralink, mais la société vise une mise sur le marché à l'horizon 2030. Le chemin reste semé d'embûches techniques, éthiques, cliniques… mais le cap est fixé : faire entrer la vision artificielle dans le réel. Et connaissant Musk, difficile de croire qu'il en restera là. Car derrière cette promesse médicale, certains voient déjà les prémices d'une interface homme-machine aux allures de science-fiction. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Die Randburgse Landdroshof in Gauteng het borgtog van 10 000 Suid-Afrikaanse rand elk toegestaan aan 12 lede van die Weermag se Spesiale Magte wat teregstaan vir die moord op 'n ondersoeker van die Valke, Frans Mathipa. Die hoof-ondersoeker in misdade teen die staat is in Augustus 2023 op die N1 naby die Hammanskraal-tolplaza vermoor terwyl hy 'n ontvoering ondersoek het. Die saak is tot Donderdag uitgestel terwyl die ondersoek voortduur. Phindi Mjonondwane van die Nasionale Vervolgingsgesag sê die borgtog-beslissing is teleurstellend:

《N1文法30天必考攻略（附考前衝刺規劃手帳）》 博客來 ，誠品 ， 金石堂 --- 官方 DISCORD：點進去跟我們互動吧 本集教學內容：教學內容 來IG學更多：EZJapan IG -- Hosting provided by SoundOn

Öll viðtölin úr þætti dagsins ásamt símatíma: Gísli Már Gíslason prófessor emeritus í líffræði um muninn á lýsmýi og bitmýi Inga Sæland, félags- og húsnæðismálaráðherra um uppbyggingu hjúkrunarheimila Símatími Sigurdís Haraldsdóttir krabbameinslæknir og yfirlæknir á Landspítala og Hulda María Einarsdóttir ristilskurðlæknir um nýja rannsókn sem gefur vísbendingar um að markviss hreyfing geti bætt lífshorfur fólks sem fengið hefur ristilkrabbamein Sævar Pétursson framkvæmdastjóri KA um N1 mótið og stemninguna á Akureyri

Heil og sæl. Í dag ræði ég við Þórhall Dan og Svanhvíti um Bestu deildina, fráfall Diogo Jota, kvennalandsliðið, Lengjudeildina, N1 mótið á Akureyri og margt fleira. Ásthildur Helgadóttir spáir svo í leik Íslands og Sviss á EM kvenna í knattspyrnu auk þess sem við við förum aðeins í síðasta leik Íslands sem var tap gegn finnum. Þetta og margt fleira kæru hlustendur og takk fyrir að hlusta. 

《N1文法30天必考攻略（附考前衝刺規劃手帳）》 博客來 ，誠品 ， 金石堂 --- 官方 DISCORD：點進去跟我們互動吧 本集教學內容：教學內容 來IG學更多：EZJapan IG -- Hosting provided by SoundOn

《N1文法30天必考攻略（附考前衝刺規劃手帳）》 博客來 ，誠品 ， 金石堂 --- 官方 DISCORD：點進去跟我們互動吧 本集教學內容：教學內容 來IG學更多：EZJapan IG -- Hosting provided by SoundOn

《N1文法30天必考攻略（附考前衝刺規劃手帳）》 博客來 ，誠品 ， 金石堂 --- 官方 DISCORD：點進去跟我們互動吧 本集教學內容：教學內容 來IG學更多：EZJapan IG -- Hosting provided by SoundOn

EZCourse與李歐日文合作「李歐日文50音速記班」線上課程， 現在輸入折扣碼: anone150 可以再折150元，折扣碼使用期限：2025.06.25~2025.07.13 課程連結：李歐日文50音速記班 李歐老師助詞課「李歐日文助詞一次搞懂！從例句帶你掌握用法差異」 填寫問卷就能在開課前獲得300元課程折價券 並馬上下載「日文助詞 × 動詞搭配表」 問卷連結：https://pse.is/7s899y ---- 《N1文法30天必考攻略（附考前衝刺規劃手帳）》 博客來 ，誠品 ， 金石堂 --- 官方 DISCORD：點進去跟我們互動吧 來IG學更多：EZJapan IG -- Hosting provided by SoundOn

《N1文法30天必考攻略（附考前衝刺規劃手帳）》 博客來 ，誠品 ， 金石堂 --- 官方 DISCORD：點進去跟我們互動吧 本集教學內容：教學內容 來IG學更多：EZJapan IG -- Hosting provided by SoundOn

Izrael intenzivira napade nakon što je Iran pogodio izraelsku bolnicu. Donosimo priču o tome kako su urednici United medija, u okviru koje posluju i N1 i Nova širom regiona, zabrinuti zbog mogućeg političkog uticaja. Poslušajte i priču kako danas žive ženE silovane tokom rata u Bosni i Hercegovini.

Advokat Božo Prelević za N1 rekao je da građani moraju da povrate suverenitet nad svojim gradom, institucijama i državom, jer je, kako kaže - "država naša". "Odgovornost leži na svima, ali bih voleo da vidim tu sinergiju gde nećemo isključivati nikog ko nešto može da promeni", ističe.

《N1文法30天必考攻略（附考前衝刺規劃手帳）》 博客來 ，誠品 ， 金石堂 --- 官方 DISCORD：點進去跟我們互動吧 本集教學內容：教學內容 來IG學更多：EZJapan IG -- Hosting provided by SoundOn

《N1文法30天必考攻略（附考前衝刺規劃手帳）》 博客來 ，誠品 ， 金石堂 --- 官方 DISCORD：點進去跟我們互動吧 本集教學內容：教學內容 來IG學更多：EZJapan IG -- Hosting provided by SoundOn

La marche était trop haute pour Loïs Boisson. La Française s'est inclinée en deux petits sets contre Coco Gauff en demi-finale du Grand Chelem parisien. Malgré cette défaite, sa quinzaine reste incroyable ! Elle est désormais 65e mondiale et N1 française... Où placer cet exploit dans l'histoire du tennis Français ? L'équipe revient sur la folle aventure de la Dijonnaise sans oublier le débrief du match entre Sabalenka et Swiatek. Dans la 2e partie de l'émission, pronostics des demies hommes. Au menu, deux chocs : Musetti vs Alcaraz et Djokovic vs Sinner. Quelle sera l'affiche de la finale ?

《N1文法30天必考攻略（附考前衝刺規劃手帳）》 博客來 ，誠品 ， 金石堂 --- 官方 DISCORD：點進去跟我們互動吧 本集教學內容：教學內容 來IG學更多：EZJapan IG -- Hosting provided by SoundOn

《N1文法30天必考攻略（附考前衝刺規劃手帳）》 博客來 ，誠品 ， 金石堂 --- 官方 DISCORD：點進去跟我們互動吧 本集教學內容：教學內容 來IG學更多：EZJapan IG -- Hosting provided by SoundOn

《N1文法30天必考攻略（附考前衝刺規劃手帳）》 博客來 ，誠品 ， 金石堂 --- 官方 DISCORD：點進去跟我們互動吧 本集教學內容：教學內容 來IG學更多：EZJapan IG -- Hosting provided by SoundOn

"Jasno je da su u krizi i vlast i univerzitet - Vučić ne poseže za izborima kada želi da izađe iz situacije koja je za njena neprijatna, što je njegov uobičajeni trik - a univerzitet, jer postoji pad entuzijazma i nervoza među članovima akademske zajednice", kaže za N1 profesor Pravnog fakulteta Univerziteta u Beogradu Tanasije Marinković. On naglašava da onlajn nastava nije u skladu sa Zakonom o visokom obrazovanju, kao i da je potrebno formulisati nove vidove demokratske borbe.

即將邁入50歲，在金融業擔任高階主管的她，意外被迫離開職場。沒有名片、沒有身份，她該迅速回到職場？或是轉身投入家庭？她要如何重啟人生？ 這集節目的來賓是嫺人，在「被退休」後，她立即為自己賦予了3個新身份：管理自己退休金的經理人、部落格版主，以及英日語導遊候選人。於是她開始為自己的退休金務實理財、將心得寫在部落格，用功學日文甚至還通過日本能力N1的檢定，考取了英日語導遊以及外語領隊證照⋯⋯這些看似天馬行空的決定，如今都因為她的積極行動ㄒ而逐一開花結果。 她是怎麼做到的？ 嫺人分享： - 中年意外退休之後，如何為自己賦予新角色？ - 「清單控」也能用來規劃退休生活？ - 退休後，你會比自己想像的還抒懶？ - 如何維持學習的動力？ - 退休金要多少才夠？如何計算？ 主持人：《慢老》作者、天下雜誌網路專欄作者 黃惠如 來賓：《嫺人的好日子》部落格版主 嫺人 製作團隊：張雅媛、劉駿逸 ＊訂閱天下全閱讀：https://bit.ly/3STpEpV ＊下載天下雜誌App：https://bit.ly/3ELcwhX ＊意見信箱：bill@cw.com.tw -- Hosting provided by SoundOn

《N1文法30天必考攻略（附考前衝刺規劃手帳）》 博客來 ，誠品 ， 金石堂 --- 官方 DISCORD：點進去跟我們互動吧 本集教學內容：教學內容 來IG學更多：EZJapan IG -- Hosting provided by SoundOn

《N1文法30天必考攻略（附考前衝刺規劃手帳）》 博客來 ，誠品 ， 金石堂 --- 官方 DISCORD：點進去跟我們互動吧 本集教學內容：教學內容 來IG學更多：EZJapan IG -- Hosting provided by SoundOn

《N1文法30天必考攻略（附考前衝刺規劃手帳）》 博客來 ，誠品 ， 金石堂 --- 官方 DISCORD：點進去跟我們互動吧 本集教學內容：教學內容 來IG學更多：EZJapan IG -- Hosting provided by SoundOn

Like the saying goes, "better late than never", the Camerosity Podcast is back with Episode 91, which is dedicated to cameras of the 90s.  Which 90s you prefer, 1890s or 1990s, all 90s cameras are welcome! Joining Anthony, Paul, Theo, Stephen, and Mike are returning callers, AJ Gentile, Ira Cohen, Miles Libak, Nick Marshall, Robert Rotoloni, and Will Pinkham and we cover a wide range of 1990s cameras and technologies.  Paul starts off with some stories about mini labs and how single use cameras became a big thing.  We dive into bridge cameras, including the Olympus IS-2 which Mike gave rave remarks to. We discuss a large number of point and shoot cameras including premium models by Nikon and Konica, and ponder why the Olympus Stylus Epic is so popular today.  We talk about some dead end technologies from the 90s such as Minolta's ill fated Creative Expansion and Canon's obscure barcode scanner for the EOS 10S. Not all technologies from the 1990s were failures though as the 1990s was the first decade of digital cameras.  Models like the floppy disc Sony Mavica and Nikon D1 were great cameras with a historical significance which helped prove that digital photography had arrived. We round out the discussion with why Theo loves the Mamiya 7 so much and how it compares to the Mamiya 6, Robert shares some info on the development of the Nikon S3 2000 edition, and we have a thorough discussion on Kyocera's Contax SLRs. As always, the topics we discuss on the Camerosity Podcast are influenced by you!  Please don't feel like you have to be an expert on a specific type of camera, or have the level of knowledge on par with other people on the show.  We LOVE people who are into shooting or collecting cameras, no matter how long you've been doing it, so please don't consider your knowledge level to be a prerequisite for joining! The guys and I rarely know where each episode is going to go until it happens, so if you'd like to join us on a future episode, be sure to look out for our show announcements on our Camerosity Podcast Facebook page, the Camerosity Discord server, and right here on mikeeckman.com. We usually record every other Monday and announcements, along with the Zoom link are typically shared 2-3 days in advance. For our next episode, we decided to explore the Italian camera industry as its not often discussed in camera collector circles.  While Germany, Japan, the Soviet Union, and the United States were well known as makers of fine cameras, a great number of really cool cameras were made in Italy such as the Rectaflex, Ducati Sogno, Gamma II, and other models by Bencini, Durst, and Ferrania.  Join us if you're a fan of cameras from this "boot shaped" country, and see if we can manage to fill an entire episode without getting distracted!  We will record Episode 92 on Monday, May 19th at 7pm Central Daylight Time and 8pm Eastern Daylight Time. In This Episode Jeff and Gabe Can't Pronounce French Names / Alan Peres Sends Us Emails Now Sometimes Its Hard to Remember That We Like Cameras from the 1990s The 1990s Was the Decade of the MiniLab and Single Use Disposable Cameras Olympus Invested Heavily in Point and Shoots in the late 1980s In the 1990s, Olympus Gave Up on Traditional SLRs and Created the IS-Series Olympus IS-2 / In the 90s Zoom Reach was Over Valued By Novices Why Are the Olympus Stylus Epics so Expensive? / µ[mju:]-II Nikon F5 Improvements Over the F4 / Paul Really Hates the Nikon N70 The Nikon N90/F90 Was Nikons Best Semi-Pro SLR of the 1990s Broken Battery and Film Doors Were a Huge Problem Back Then The Nikon 28Ti and 35Ti Are Impressive Cameras but Terrible Investments 1990s Underwater Cameras / How Many People Kept Shooting 80s Cameras in the 90s? Contax S2 and Other 1990s Contax SLRs / Contax S2 and ST Mike Likes the Contax RTS II and the Contax RX / Large Contaxes Like the N1 and AX The Minolta Maxxum 600si/650si Has Mechanical Knobs and is Awesome / Minolta Maxxum 9xi Minolta's Horrible Creative Expansion Cards / Disabling Features on Consumer SLRs / Canon Barcode Scanning System The Canon EOS-1n RS / Pellicle Mirrors / Canon EOS A2E / Canon's Eye Control System Premium Point and Shoots / Konica Hexar AF / Canon Elph Theo Loves the Mamiya 7 / Mamiya 6 / Everyone's First 110 Camera Nikon Started Working on the S3 2000 in the 1990s / Differences Between the 2000 and Original S3 Sony Floppy Mavica Cameras / Nikon D1 Alfred C. Kemper Kombi from the 1890s / Theo's 1890s Australian Studio Cameras Advanced Photo System (APS) Film and Cameras / Kodak Advantix Preview Links The Camerosity Podcast is now on Discord! Join Anthony, Paul, Theo, and Mike on our very own Discord Server. Share your GAS and photography with other listeners in the Lounge or in our dedicated forums. If you have questions for myself or the other guys, we have an “Ask the Hosts” section as well where you can get your question answered on a future show! Check it out! https://discord.gg/PZVN2VBJvm. If you would like to offer feedback or contact us with questions or ideas for future episodes, please contact us in the Comments Section below, our Camerosity Facebook Group, Instagram page, or Discord server. The Official Camerosity Facebook Group - https://www.facebook.com/groups/camerositypodcast Camerosity Instagram - https://www.instagram.com/camerosity_podcast/ Keppler's Vault 101: Advanced Photo System - https://mikeeckman.com/2022/03/kepplers-vault-101-advanced-photo-system/ Theo Panagopoulos - https://www.photothinking.com/ Paul Rybolt - https://www.ebay.com/usr/paulkris - https://thisoldcamera.net/ Anthony Rue - https://www.instagram.com/kino_pravda/

Action Society sê die vryspraak van agt polisiebeamptes van adjunkpresident Paul Mashatile se BBP-beskermingseenheid is 'n ernstige terugslag vir geregtigheid en polisie-aanspreeklikheid. Die beamptes, bekend as die “blouligmafia”, is in Julie 2023 op die N1-snelweg in Johannesburg afgeneem terwyl hulle burgerlikes aangerand het, maar is in 'n interne dissiplinêre verhoor vrygespreek. Woordvoerder van die organisasie, Juanita du Preez, sê die uitslag stuur 'n gevaarlike boodskap en traumatiseer die slagoffers opnuut:

Dr. Ko Un “Clara” Park and Dr. Mylin Torres present the latest evidence-based changes to the SLNB in early-stage breast cancer guideline. They discuss the practice-changing trials that led to the updated recommendations and topics such as when SLNB can be omitted, when ALND is indicated, radiation and systemic treatment decisions after SLNB omission, and the role of SLNB in special circumstances. We discuss the importance of shared decision-making and other ongoing and future de-escalation trials that will expand knowledge in this space. Read the full guideline update, “Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update” at www.asco.org/breast-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/breast-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-00099       Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Ko Un "Clara" Park from Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Dr. Mylin Torres from Glenn Family Breast Center at Winship Cancer Institute of Emory University, co-chairs on “Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.” Thank you for being here today, Dr. Park and Dr. Torres. Dr. Mylin Torres: Thank you, it's a pleasure to be here. Brittany Harvey: And before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Torres and Dr. Park, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. To start us off, Dr. Torres, what is the scope and purpose of this guideline update on the use of sentinel lymph node biopsy in early-stage breast cancer? Dr. Mylin Torres: The update includes recommendations incorporating findings from trials released since our last published guideline in 2017. It includes data from nine randomized trials comparing sentinel lymph node biopsy alone versus sentinel lymph node biopsy with a completion axillary lymph node dissection. And notably, and probably the primary reason for motivating this update, are two trials comparing sentinel lymph node biopsy with no axillary surgery, all of which were published from 2016 to 2024. We believe these latter two trials are practice changing and are important for our community to know about so that it can be implemented and essentially represent a change in treatment paradigms. Brittany Harvey: It's great to hear about these practice changing trials and how that will impact these recommendation updates. So Dr. Park, I'd like to start by reviewing the key recommendations across all of these six overarching clinical questions that the guideline addressed. So first, are there patients where sentinel lymph node biopsy can be omitted? Dr. Ko Un "Clara" Park: Yes. The key change in the current management of early-stage breast cancer is the inclusion of omission of sentinel lymph node biopsy in patients with small, less than 2 cm breast cancer and a negative finding on preoperative axillary ultrasound. The patients who are eligible for omission of sentinel lymph node biopsy according to the SOUND and INSEMA trial are patients with invasive ductal carcinoma that is size smaller than 2 cm, Nottingham grades 1 and 2, hormone receptor-positive, HER2-negative in patients intending to receive adjuvant endocrine therapy, and no suspicious lymph nodes on axillary ultrasound or if they have only one suspicious lymph node, then the biopsy of that lymph node is benign and concordant according to the axillary ultrasound findings. The patients who are eligible for sentinel lymph node biopsy omission according to the SOUND and INSEMA trials were patients who are undergoing lumpectomy followed by whole breast radiation, especially in patients who are younger than 65 years of age. For patients who are 65 years or older, they also qualify for omission of sentinel lymph node biopsy in addition to consideration for radiation therapy omission according to the PRIME II and CALGB 9343 clinical trials. And so in those patients, a more shared decision-making approach with the radiation oncologist is encouraged. Brittany Harvey: Understood. I appreciate you outlining that criteria for when sentinel lymph node biopsy can be omitted and when shared decision making is appropriate as well. So then, Dr. Torres, in those patients where sentinel lymph node biopsy is omitted, how are radiation and systemic treatment decisions impacted? Dr. Mylin Torres: Thank you for that question. I think there will be a lot of consternation brought up as far as sentinel lymph node biopsy and the value it could provide in terms of knowing whether that lymph node is involved or not. But as stated, sentinel lymph node biopsy actually can be safely omitted in patients with low risk disease and therefore the reason we state this is that in both SOUND and INSEMA trial, 85% of patients who had a preoperative axillary ultrasound that did not show any signs of a suspicious lymph node also had no lymph nodes involved at the time of sentinel node biopsy. So 85% of the time the preoperative ultrasound is correct. So given the number of patients where preoperative ultrasound predicts for no sentinel node involvement, we have stated within the guideline that radiation and systemic treatment decisions should not be altered in the select patients with low risk disease where sentinel lymph node biopsy can be omitted. Those are the patients who are postmenopausal and age 50 or older who have negative findings on preoperative ultrasound with grade 1 or 2 disease, small tumors less than or equal to 2 cm, hormone receptor-positive, HER2-negative breast cancer who undergo breast conserving therapy. Now, it's important to note in both the INSEMA and SOUND trials, the vast majority of patients received whole breast radiation. In fact, within the INSEMA trial, partial breast irradiation was not allowed. The SOUND trial did allow partial breast irradiation, but in that study, 80% of patients still received whole breast treatment. Therefore, the preponderance of data does support whole breast irradiation when you go strictly by the way the SOUND and INSEMA trials were conducted. Notably, however, most of the patients in these studies had node-negative disease and had low risk features to their primary tumors and would have been eligible for partial breast irradiation by the ASTRO Guidelines for partial breast treatment. So, given the fact that 85% of patients will have node-negative disease after a preoperative ultrasound, essentially what we're saying is that partial breast irradiation may be offered in these patients where omission of sentinel node biopsy is felt to be safe, which is in these low risk patients. Additionally, regional nodal irradiation is something that is not indicated in the vast majority of patients where omission of sentinel lymph node biopsy is prescribed and recommended, and that is because very few of these patients will actually end up having pathologic N2 disease, which is four or more positive lymph nodes. If you look at the numbers from both the INSEMA and the SOUND trial, the number of patients with pathologic N2 disease who did have their axilla surgically staged, it was less than 1% in both trials. So, in these patients, regional nodal irradiation, there would be no clear indication for that more aggressive and more extensive radiation treatment. The same principles apply to systemic therapy. As the vast majority of these patients are going to have node-negative disease with a low risk primary tumor, we know that postmenopausal women, even if they're found to have one to three positive lymph nodes, a lot of the systemic cytotoxic chemotherapy decisions are driven by genomic assay score which is taken from the primary tumor. And therefore nodal information in patients who have N1 disease may not be gained in patients where omission of sentinel lymph node biopsy is indicated in these low risk patients. 14% of patients have 1 to 3 positive lymph nodes in the SOUND trial and that number is about 15% in the INSEMA trial. Really only the clinically actionable information to be gained is if a patient has four or more lymph nodes or N2 disease in this low risk patient population. So, essentially when that occurs it's less than 1% of the time in these patients with very favorable primary tumors. And therefore we thought it was acceptable to stand by a recommendation of not altering systemic therapy or radiation recommendations based on omission of sentinel nodes because the likelihood of having four more lymph nodes is so low. Dr. Ko Un "Clara" Park: I think one thing to add is the use of CDK4/6 inhibitors to that and when we look at the NATALEE criteria for ribociclib in particular, where node-negative patients were included, the bulk majority of the patients who were actually represented in the NATALEE study were stage III disease. And for stage I disease to upstage into anatomic stage III, that patient would need to have pathologic N2 disease. And as Dr. Torres stated, the rate of having pathologic N2 disease in both SOUND and INSEMA studies were less than 1%. And therefore it would be highly unlikely that these patients would be eligible just based on tumor size and characteristics for ribociclib. So we think that it is still safe to omit sentinel lymph node biopsy and they would not miss out, if you will, on the opportunity for CDK4/6 inhibitors. Brittany Harvey: Absolutely. I appreciate you describing those recommendations and then also the nuances of the evidence that's underpinning those recommendations, I think that's important for listeners. So Dr. Park, the next clinical question addresses patients with clinically node negative early stage breast cancer who have 1 or 2 sentinel lymph node metastases and who will receive breast conserving surgery with whole breast radiation therapy. For these patients, is axillary lymph node dissection needed? Dr. Ko Un "Clara" Park: No. And this is confirmed based on the ACOSOG Z0011 study that demonstrated in patients with 1 to 3 positive sentinel lymph node biopsy when the study compared completion axillary lymph node dissection to no completion axillary lymph node dissection, there was no difference. And actually, the 10-year overall survival as reported out in 2017 and at a median follow up of 9.3 years, the overall survival again for patients treated with sentinel lymph node biopsy alone versus those who were treated with axillary lymph node dissection was no different. It was 86.3% in sentinel lymph node biopsy versus 83.6% and the p-value was non-inferior at 0.02. And so we believe that it is safe for the select patients who are early stage with 1 to 2 positive lymph nodes on sentinel lymph node biopsy, undergoing whole breast radiation therapy to omit completion of axillary lymph node dissection. Brittany Harvey: Great, I appreciate you detailing what's recommended there as well. So then, to continue our discussion of axillary lymph node dissection, Dr. Torres, for patients with nodal metastases who will undergo mastectomy, is axillary lymph node dissection indicated? Dr. Mylin Torres: It's actually not and this is confirmed by two trials, the AMAROS study as well as the SENOMAC trial. And in both studies, they compared a full lymph node dissection versus sentinel lymph node biopsy alone in patients who are found to have 1 to 2 positive lymph nodes and confirmed that there was no difference in axillary recurrence rates, overall survival or disease-free survival. What was shown is that with more aggressive surgery completion axillary lymph node dissection, there were higher rates of morbidity including lymphedema, shoulder pain and paresthesias and arm numbness, decreased functioning of the arm and so there was only downside to doing a full lymph node dissection. Importantly, in both trials, if a full lymph node dissection was not done in the arm that where sentinel lymph node biopsy was done alone, all patients were prescribed post mastectomy radiation and regional nodal treatment and therefore both studies currently support the use of post mastectomy radiation and regional nodal treatment when a full lymph node dissection is not performed in these patients who are found to have N1 disease after a sentinel node biopsy. Brittany Harvey: Thank you. And then Dr. Park, for patients with early-stage breast cancer who do not have nodal metastases, can completion axillary lymph node dissection be omitted? Dr. Ko Un "Clara" Park: Yes, and this is an unchanged recommendation from the earlier ASCO Guidelines from 2017 as well as the 2021 joint guideline with Ontario Health, wherein patients with clinically node-negative early stage breast cancer, the staging of the axilla can be performed through sentinel lymph nodal biopsy and not completion axillary lymph node dissection. Brittany Harvey: Understood. So then, to wrap us up on the clinical questions here, Dr. Park, what is recommended regarding sentinel lymph node biopsy in special circumstances in populations? Dr. Ko Un "Clara" Park: One key highlight of the special populations is the use of sentinel lymph node biopsy for evaluation of the axilla in clinically node negative multicentric tumors. While there are no randomized clinical trials evaluating specifically the role of sentinel lymph nodal biopsy in multicentric tumors, in the guideline, we highlight this as one of the safe options for staging of the axilla and also for pregnant patients, these special circumstances, it is safe to perform sentinel lymph node biopsy in pregnant patients with the use of technetium - blue dye should be avoided in this population. In particular, I want to highlight where sentinel lymph node biopsy should not be used for staging of the axilla and that is in the population with inflammatory breast cancer. There are currently no studies demonstrating that sentinel lymph node biopsy is oncologically safe or accurate in patients with inflammatory breast cancer. And so, unfortunately, in this population, even after neoadjuvant systemic therapy, if they have a great response, the current guideline recommends mastectomy with axillary lymph node dissection. Brittany Harvey: Absolutely. I appreciate your viewing both where sentinel lymph node can be offered in these special circumstances in populations and where it really should not be used. So then, Dr. Torres, you talked at the beginning about how there's been these new practice changing trials that really impacted these recommendations. So in your view, what is the importance of this guideline update and how does it impact both clinicians and patients? Dr. Mylin Torres: Thank you for that question. This update and these trials that inform the update represent a significant shift in the treatment paradigm and standard of care for breast cancer patients with early-stage breast cancer. When you think about it, it seems almost counterintuitive that physicians and patients would not want to know if a lymph node is involved with cancer or not through sentinel lymph node biopsy procedure. But what these studies show is that preoperative axillary ultrasound, 85% of the time when it's negative, will correctly predict whether a sentinel lymph node is involved with cancer or not and will also be negative. So if you have imaging that's negative, your surgery is likely going to be negative. Some people might ask, what's the harm in doing a sentinel lymph node biopsy? It's important to recognize that upwards of 10% of patients, even after sentinel lymph node biopsy will develop lymphedema, chronic arm pain, shoulder immobility and arm immobility. And these can have a profound impact on quality of life. And if there is not a significant benefit to assessing lymph nodes, particularly in someone who has a preoperative axillary ultrasound that's negative, then why put a patient at risk for these morbidities that can impact them lifelong? Ideally, the adoption of omission of sentinel lymph node biopsy will lead to more multidisciplinary discussion and collaboration in the preoperative setting especially with our diagnostic physicians, radiology to assure that these patients are getting an axillary ultrasound and determine how omission of sentinel lymph node biopsy may impact the downstream treatments after surgery, particularly radiation and systemic therapy decisions, and will be adopted in real world patients, and how clinically we can develop a workflow where together we can make the best decisions for our patients in collaboration with them through shared decision making. Brittany Harvey: Absolutely. It's great to have these evidence-based updates for clinicians and patients to review and refer back to. So then finally, Dr. Park, looking to the future, what are the outstanding questions and ongoing trials regarding sentinel lymph node biopsy in early-stage breast cancer? Dr. Ko Un "Clara" Park: I think to toggle on Dr. Torres's comment about shared decision making, the emphasis on that I think will become even more evident in the future as we incorporate different types of de-escalation clinical studies. In particular, because as you saw in the SOUND and INSEMA studies, when we de-escalate one modality of the multimodality therapy, i.e., surgery, the other modalities such as radiation therapy and systemic therapy were “controlled” where we were not de-escalating multiple different modalities. However, as the audience may be familiar with, there are other types of de-escalation studies in particular radiation therapy, partial breast irradiation or omission of radiation therapy, and in those studies, the surgery is now controlled where oftentimes the patients are undergoing surgical axillary staging. And conversely when we're looking at endocrine therapy versus radiation therapy clinical trials, in those studies also the majority of the patients are undergoing surgical axillary staging. And so now as those studies demonstrate the oncologic safety of omission of a particular therapy, we will be in a position of more balancing of the data of trying to select which patients are the safe patients for omission of certain types of modality, and how do we balance whether it's surgery, radiation therapy, systemic therapy, endocrine therapy. And that's where as Dr. Torres stated, the shared decision making will become critically important. I'm a surgeon and so as a surgeon, I get to see the patients oftentimes first, especially when they have early-stage breast cancer. And so I could I guess be “selfish” and just do whatever I think is correct. But whatever the surgeon does, the decision does have consequences in the downstream decision making. And so the field really needs to, as Dr. Torres stated earlier, rethink the workflow of how early-stage breast cancer patients are brought forth and managed as a multidisciplinary team. I also think in future studies the expansion of the data to larger tumors, T3, in particular,reater than 5 cm and also how do we incorporate omission in that population will become more evident as we learn more about the oncologic safety of omitting sentinel lymph node biopsy. Dr. Mylin Torres: In addition, there are other outstanding ongoing clinical trials that are accruing patients right now. They include the BOOG 2013-08 study, SOAPET, NAUTILUS and the VENUS trials, all looking at patients with clinical T1, T2N0 disease and whether omission of sentinel lymph node biopsy is safe with various endpoints including regional recurrence, invasive disease-free survival and distant disease-free survival. I expect in addition to these studies there will be more studies ongoing even looking at the omission of sentinel lymph node biopsy in the post-neoadjuvant chemotherapy setting. And as our imaging improves in the future, there will be more studies improving other imaging modalities, probably in addition to axillary ultrasound in an attempt to accurately characterize whether lymph nodes within axilla contain cancer or not, and in that context whether omission of sentinel lymph node biopsy even in patients with larger tumors post-neoadjuvant chemotherapy may be done safely and could eventually become another shift in our treatment paradigm. Brittany Harvey: Yes. The shared decision making is key as we think about these updates to improve quality of life and we'll await data from these ongoing trials to inform future updates to this guideline. So I want to thank you both so much for your extensive work to update this guideline and thank you for your time today. Dr. Park and Dr. Torres. Dr. Mylin Torres: Thank you. Dr. Ko Un "Clara" Park: Thank you. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/breast-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

About the Guest: Caroline Tracey is a distinguished writer focusing on topics related to art, literature, environment, and migration in the U.S., the Southwest, Mexico, and borderland regions. Caroline contributes to the Border Chronicle, among other reputable publications such as N1, The Nation, and The Guardian. Not only does she have expertise in English, but she is also trilingual, proficient in Spanish and Russian. Caroline's significant contributions to journalism include winning the 2019 Scoundrel Time Summer Literary Seminars nonfiction contest for her work on migrant deaths in South Texas. With a PhD in geography from UC Berkeley, Caroline is currently working on a book about salt lakes, set to be published by W.W. Norton. Episode Summary: In this episode of "90 Miles from Needles," host Chris Clarke converses with Caroline Tracey, a talented journalist with a focus on the borderlands of the U.S. and Mexico. The discussion revolves around Plan Sonora, a significant energy transition and development initiative in the Mexican state of Sonora, which borders the U.S. state of Arizona. Through this lens, Caroline explores the impacts of renewable and fossil fuel energy developments, such as lithium mining and solar arrays, on both local ecosystems and indigenous communities. Her insights underscore the complex balance between industrial progress and environmental conservation. The episode gives an in-depth look at Plan Sonora's four key components: a major solar array in Rocky Point, the nationalization of lithium mining reserves, an expansive natural gas pipeline project, and logistic developments that aim to transform Sonora into an economic hub. Caroline delves into activism efforts against these developments, particularly highlighting successful campaigns led by environmental groups against the Mexico Pacific's Saguaro Energy Project. By doing so, she paints a vivid picture of the current tensions between commercial ambitions and advocacy for ecological protection and cultural preservation. Key Takeaways: Plan Sonora: This encompasses solar power projects, lithium mining, natural gas pipeline proposals, and logistical developments, transforming Sonora into a critical player in renewable energy. Cross-border Impacts: Renewable energy developments in Mexico cater largely to U.S. demands, raising concerns about "green colonialism." Opposition and Activism: Indigenous communities and environmental activists are actively opposing certain projects due to cultural and environmental implications, most notably the pipeline and terminal proposals along the Gulf of California. Political Dynamics: Recent changes in Mexico's administration and judicial system reform are smoothing the way for energy investment and curtailing environmental regulations. Economic and Environmental Tensions: Despite opportunities for economic growth, critics argue these projects risk damaging vital ecosystems and stripping local communities of benefits. Notable Quotes: "Personally, I increasingly think that enlisting large corporations to do your climate mitigation work is inevitably going to kick you in the butt." - Chris Clarke "They plan to build a couple other solar plants that are of similar size…[in] the Gulf of California." - Caroline Tracey "There are four pipelines that are being developed right now…[raising] economic development to the detriment of people in Mexico." - Caroline Tracey "If indeed we're going to transition to renewable energy, that means first of all, stopping new extraction projects." - Caroline Tracey Resources: Caroline Tracey’s work at the Border Chronicle: https://www.theborderchronicle.com Caroline Tracey’s personal website: https://cetracey.com Ballenas ó Gas in Spanish: https://ballenasogas.org/ and in English: https://whalesorgas.org/ Article by By Martha Pskowski, Inside Climate News, and Alejandra Martinez, the Texas Tribune on opposition to the Saguaro Pipeline in Van Horn, TX: https://insideclimatenews.org/news/20122023/west-texans-rally-against-cross-border-pipeline/ Stay tuned to "90 Miles from Needles" for more enlightening discussions on desert protection and environmental advocacy.Become a desert defender!: https://90milesfromneedles.com/donateSee omnystudio.com/listener for privacy information.

In this deep dive episode, we look at how sleep onset can help creativity. With our amazing guest speakers, Professor Bob Stickgold, Dr Adam Horowitz, Professor Delphine Oudiette and Dr Celia Lacaux, we take a look at their work on creativity, dreams and N1 sleep. Together, we discuss different definitions of creativity, what defines N1 and what it is about N1 that makes it prime time for creative processing. Find out more about our guest speakers:Professor Bob StickgoldDr Adam HorowitzProfessor Delphine OudietteDr Celia LacauxPapers from the episode:Sleep onset is a creative sweetspot Replaying the Game: Hypnagogic Images in Normals and AmnesicsDormio: A targeted dream incubation deviceHost: Professor Penny LewisEditor: Sophie Smith Check out our NaPS website to find out more about our team, our research and events. This recording is the property of the Sleep Science Podcast and not for resale.